Related Experiment Videos
Combination therapy for dyslipidemia
1Department of Internal Medicine, University of North Texas Health Science Center at Fort Worth, USA. Cspel74111@aol.com
Insights
Achieving low-density lipoprotein cholesterol (LDL-C) targets is crucial for reducing coronary heart disease (CHD) risk. Combination therapy, including novel agents like ezetimibe, improves lipid management and patient outcomes.
Area of Science:
- Cardiology
- Pharmacology
- Metabolic Disorders
Background:
- National Cholesterol Education Program (NCEP) Adult Treatment Panel III (ATP III) guidelines emphasize low-density lipoprotein cholesterol (LDL-C) targets for coronary heart disease (CHD) risk reduction.
- Despite lifestyle changes, many patients with dyslipidemia fail to reach lipid targets, necessitating pharmacotherapy.
- Current achievement rates for LDL-C goals remain low, even in patients with existing CHD.
Purpose of the Study:
- To review the pharmacotherapeutic effects of combination lipid-lowering therapy.
- To summarize the strengths and weaknesses of current lipid-lowering drug combinations.
- To identify the impact of ezetimibe, a novel cholesterol absorption inhibitor, on the LDL-C treatment algorithm.
Main Methods:
- Review of pharmacotherapeutic effects of combination therapy.
- Summary of current lipid-lowering drug combinations, including strengths and weaknesses.
- Analysis of ezetimibe's role in cholesterol management.
Main Results:
- Combination therapy significantly enhances the likelihood of achieving target lipid levels.
- Therapeutic modalities targeting both endogenous and exogenous cholesterol pathways are ideal.
- Ezetimibe presents a potential new option within the LDL-C treatment algorithm.
Conclusions:
- Early and aggressive use of effective lipid-lowering agents is critical for reaching treatment goals.
- Combination drug therapy is essential for improving lipid management in a majority of patients.
- Ezetimibe offers a promising addition to the therapeutic arsenal for managing dyslipidemia and reducing CHD risk.
Abstract:
In the National Cholesterol Education Program (NCEP) Adult Treatment Panel III (ATP III) guidelines, the emphasis of lipid-lowering therapy is placed on reaching target plasma low-density lipoprotein cholesterol (LDL-C) levels in order to reduce the risk for coronary heart disease (CHD). Although therapeutic lifestyle changes can have a positive effect on LDL-C levels, the ATP III recognizes that a majority of patients with dyslipidemia will also require drug therapy to achieve lipid targets. Currently, only a small percentage of patients, including those with CHD, are reaching goal. Early aggressive use of the effective lipid-lowering agents currently available is critical to achieve target lipid levels in a greater number of patients. Use of drug combinations further enhances the likelihood of achieving target lipid levels. Ideally, the combination of therapeutic modalities used both the endogenous and exogenous pathways of cholesterol synthesis to reduce the amount produced in the body, as well as the amount absorbed from the diet. This article reviews the pharmacotherapeutic effects of combination therapy, summarizes the strengths and weaknesses of current lipid-lowering drug combinations, and identifies the potential impact of the novel cholesterol absorption inhibitor ezetimibe on the LDL-C treatment algorithm.